CN104825517A - Application of gynura divaricata in preparation of drugs for treating gouty arthritis - Google Patents
Application of gynura divaricata in preparation of drugs for treating gouty arthritis Download PDFInfo
- Publication number
- CN104825517A CN104825517A CN201510229635.3A CN201510229635A CN104825517A CN 104825517 A CN104825517 A CN 104825517A CN 201510229635 A CN201510229635 A CN 201510229635A CN 104825517 A CN104825517 A CN 104825517A
- Authority
- CN
- China
- Prior art keywords
- gynura divaricata
- gouty arthritis
- medicine
- gynura
- divaricata
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of gynura divaricata in the preparation of drugs for treating gouty arthritis. The animal experiment results show that gynura divaricata has a good curative effect on gouty arthritis and has a good anti-inflammation and pain-relieving effect on an animal model having gouty arthritis.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly a kind of Chinese medicine for the treatment of gouty arthritis.
Background technology
Gouty arthritis is because urate deposition causes disease damage and inflammatory reaction in joint capsule, synovial bursa, cartilage, sclerotin and its hetero-organization, it has inherited genetic factors more, be apt to occur in more than 40 years old male, be more common in Metatarsophalangeal joint, also other larger joints can be betided, especially ankle and foot joint.Its morbidity was divided into for three phases, acute arthritis phase, intermission, chronic arthritis phase.The acute arthritis phase is many in sudden onset at night, affected joints severe pain, and Metatarsophalangeal joint is often involved in starting joint, is secondly ankle, knee joint etc.Joint is red, swollen, heat and tenderness, general weakness, heating, headache etc.Sustainable 3 ~ 11 days.Drink, gluttony, overwork, catch a cold, perform the operation stimulation, psychentonia all can become outbreak inducement.Intermission mostly is several months or several years, and with Relapse rate outbreak, interval shortens, stadium extends, pathological changes joint is increased, and gradually changes into chronic arthritis.There is stiff deformity, limitation of movement in chronic arthritis phase joint.The visible tophus of about 30% patient and generation renal complication, and ureteral calculus etc.There are hypertension, kidney and cerebral arteriosclerosis, myocardial infarction late period.A few patients dies from renal failure and cardiovascular is unexpected.
Primary disease belongs to the traditional Chinese medical science " arthromyodynia ", " severe and migratory arthralgia " category, how hinder meridians by cold-damp, damp-heat arthralgia, or expectorant is turbid, or the factor such as to suffer from a deficiency of the kidney is brought out, clinically can according to the different causes of disease and symptom is dialectical treats.
The treatment of current primary disease, Chinese medicine or Western medicine are all without desirable medicine.
Summary of the invention
The present invention is directed to the deficiency of prior art, the application of Gynura divaricata in the medicine of preparation treatment gouty arthritis is provided.
The object of the present invention is achieved like this: the application of Gynura divaricata in the medicine of preparation treatment gouty arthritis.
Described pharmaceutical dosage form is decoction, mixture, tablet, capsule or granule.
Treat a medicine for gouty arthritis, effective ingredient comprises Gynura divaricata or is made up of Gynura divaricata single medical material.
Described medicine is decoction, Gynura divaricata day dose be 60 ?150 grams, sooner or later take for twice after decocting point.
Treat a medicine for gouty arthritis, effective ingredient comprises Gynura divaricata extract or is made up of independent Gynura divaricata extract.
Described medicine is mixture, tablet, capsule or granule, and Gynura divaricata extract is water extract.
The present invention is proved by zoopery, has good therapeutical effect to gouty arthritis, shows to have good antiinflammatory and analgesic activity to gouty arthritis animal model.
Detailed description of the invention
The present invention is the application of Gynura divaricata in the medicine of preparation treatment gouty arthritis.
Gynura divaricata of the present invention, has another name called Radix et Rhizoma Gynurae divaricatae, is feverfew Gynura divaricata Gynura divaricata (L.) DC. [G.oualis DC.; G.pseudo ?china (L.) DC.] herb.
The medicine of this treatment gouty arthritis can be decoction, and its effective ingredient comprises Gynura divaricata medical material or is made up of Gynura divaricata single medical material.Medicine by Gynura divaricata day dose be 60 ?150 grams, sooner or later take for twice after medicine is carried out decocting point.Preferred Gynura divaricata day, taking dose was 80-120 gram.Most preferred Gynura divaricata day, taking dose was 90 grams.
The medicine of this treatment gouty arthritis can be the peroral dosage forms such as mixture, tablet, capsule or granule, and its effective ingredient comprises Gynura divaricata extract or is made up of independent Gynura divaricata extract, and presses the pharmaceutical acceptable adjuvant of different dosage form interpolation.Gynura divaricata extract is the water extract that extraction process by water is obtained routinely.
Below in conjunction with detailed description of the invention, the present invention will be further described.
Embodiment 1 decoction
Gynura divaricata 90 grams, decocts with water 2 times, each 1.5 hours, collecting decoction, and concentration is about 1 gram of former medicine/ml medicinal liquid, and a point secondary is taken sooner or later.
Embodiment 2 decoction
Gynura divaricata 150 grams, decocts with water 2 times, each 1.5 hours, collecting decoction, and concentration is about 1 gram of former medicine/ml medicinal liquid, and a point secondary is taken sooner or later.
Embodiment 3 decoction
Gynura divaricata 60 grams, decocts with water 2 times, each 1.5 hours, collecting decoction, and concentration is about 1 gram of former medicine/ml medicinal liquid, and a point secondary is taken sooner or later.
Embodiment 4 (granule)
Prescription: calculate by weight, gained dry extract 1 part, sucrose 2.5 parts, 1.5 parts, dextrin after embodiment 1 gained water extract concentrate drying.
Method for making: extract powder is added sucrose and dextrin, mixing, makes granule, and dry, subpackage, to obtain final product.
Character: this product is filemot granule; Taste is micro-sweet, bitter.
Usage and consumption: boiled water is taken after mixing it with water, 2 ~ 3 times on the one.
Embodiment 5 (capsule)
Prescription: calculate by weight, gained dry extract 1 part, starch 2 parts after embodiment 1 gained water extract concentrate drying.
Method for making: extract powder is added starch, mixing, makes granule, dry, incapsulates and get final product.
Character: this product is capsule, content is dark-brown granule or powder; Mildly bitter flavor.
Usage and consumption: oral, one time 3,2 ~ 3 times on the one.
Embodiment 6 (tablet)
Prescription: calculate by weight, gained dry extract 1 part, starch 2 parts, Magnesium Stearate proper quantity after embodiment 1 gained water extract concentrate drying.
Method for making: extract powder is added starch, mixing, makes granule, dry, adds magnesium stearate, tabletting and get final product.
Character: this product is dark-brown tablet, mildly bitter flavor.
Usage and consumption: oral, one time 3,2 ~ 3 times on the one.
Experimental example 1. Gynura divaricata is to the preventive and therapeutic effect of gouty arthritis
1 material
1.1 laboratory animal SPF level SD rats, male, body weight 180 ?220g, 48.
1.2 instruments and reagent microplate reader; Monosodium urate (Sigma company); The Gynura divaricata medicinal liquid of embodiment 1.
2 methods
2.1 Monosodium urate solution preparations take 0.5g Monosodium urate, add 10ml normal saline, make 5% Monosodium urate suspension.
Rat is divided into blank group by body weight by 2.2 methods at random, model group, positive group, the basic, normal, high dosage group of Gynura divaricata, blank group and model group gavage tap water, all the other respectively organize the corresponding medicinal liquid of gavage (the Gynura divaricata medicinal liquid of Example 1, be diluted to three kinds of medicinal liquids that concentration is 0.225 gram of former medicine/ml, 0.45 gram of former medicine/ml, 0.9 gram of former medicine/ml respectively), administration volume is 10ml/kg, every day 1 time, continuous 7d.After 5th day administration 1h, on the right side of blank group rat, ankle joint dorsal part injection physiological saline solution 0.2ml, injects 0.2 Monosodium urate suspension in Rat Right ankle joint chamber for other each group.Administration is continued, once a day, until rat is put to death after modeling.
2.3 Articular swelling measure and measure right ankle joint girth respectively at modeling 0h, 2h, 8h, 24h, and calculate ankle swelling degree.The computing formula of swelling is as follows:
Swelling (%)=(minute point ankle joint Zhou Chang ?original perimeter)/original perimeter x100%
2.4 statistical method are originally tested all results mean ± standard deviation (± s) and are represented.Adopt prism statistical software, compare group difference, using 0.05 or 0.01 as significant difference mark by one factor analysis of variance method (One ?Way ANOVA).
The impact of 3 results on acute gouty arthritis ankle swelling in rat degree the results are shown in Table 1.Visible compared with blank group by table 1, model group rats ankle joint obvious tumefaction, illustrates modeling success.Compared with model group, positive control drug colchicine treated animal all obviously declines (compared with model group in administration 2,8,24 hours posterior joint swellings, P < 0.05), in Gynura divaricata, dosage treated animal all obviously declines in administration 2,8,24 hours posterior joint swellings, wherein 8,24 hours posterior joint swelling decline degree have significant difference with compared with model group, P < 0.05.
Table 1 Gynura divaricata is on the impact (± s, n=8) of acute gouty arthritis in rats ankle swelling degree
Compared with blank group, * P < 0.05, * * P < 0.01; Compared with model group,
#p < 0.05,
##p < 0.01.
4 conclusions
The change of acute gouty arthritis or stage of attack is mainly synovial membrane inflammatory cell infiltration, uric acid deposition, tissue local necrosis, early stage urate crystal comes off from the synovial membrane of calmness and enters synovial fluid, protein in synovial fluid is adsorbed in the surface of crystallization immediately, and engulfed by synovial cell, multinuclear leucocyte, monocyte, macrophage, synovial membrane surface hyperemia edema, cell infiltration.This experimental result shows, in Gynura divaricata decocting liquid, dosage group to a certain degree can reduce the Articular swelling of gouty arthritis rat model, and prompting Gynura divaricata has certain therapeutical effect in this concentration to gouty arthritis.
Analgesic activity research (writhing method) of experimental example 2. Gynura divaricata
1 material
1.1 laboratory animal SPF level kunming mices, male, body weight 18 ?22g, 50.
1.2 instruments and reagent gastric perfusion needle; 0.6% acetum; Tramadol hydrochloride; The Gynura divaricata medicinal liquid of embodiment 1.
2 methods
Mice is divided into blank group by body weight, tramadol hydrochloride group, the basic, normal, high dosage group of Gynura divaricata by 2.1 grouping administrations at random.Blank group gavage tap water, all the other respectively organize the corresponding medicinal liquid of gavage, and administration volume is 10ml/kg.After administration 1h, every mouse peritoneal injects 0.6% acetic acid (volume injected is: 0.1ml/10g, acetic acid prepared before use).
2.2 observed and recordeds are observed and are occurred the number of times (abdominal part shrinks indent, stretches hind leg) of writhing response after recording injection acetum in 15min.Writhing response suppression ratio calculates: inhibition percentage (%)=(blank group average writhing Shuo ?administration group average writhing number)/average writhing number x100% of blank group.
2.3 statistical method are originally tested all results mean ± standard deviation (± s) and are represented.Adopt prism statistical software, compare group difference, using 0.05 or 0.01 as significant difference mark by one factor analysis of variance method (One ?Way ANOVA).
3 results the results are shown in Table 2.Compared with blank group, Gynura divaricata basic, normal, high dosage group writhing number of times all obviously reduces.Illustrate that Gynura divaricata has stronger analgesic activity.
Analgesic activity research (± s, n=10) of table 2 Gynura divaricata
Compared with blank group, * P < 0.05, * * P < 0.01
4 conclusion experimental results show, the analgesic effect of Gynura divaricata is obvious, and the pain reaction that acetic acid stimulation abdominal cavity mucosa can be suppressed to cause, reduces writhing number of times.
Analgesic activity research (writhing method) of experimental example 3. Gynura divaricata
1 material
1.1 laboratory animal SPF level kunming mices, male, body weight 18 ?22g, 50.
1.2 instruments and reagent gastric perfusion needle; Intelligence hot-plate instrument; Tramadol hydrochloride; The Gynura divaricata medicinal liquid of embodiment 1.
2 methods
Mice is divided into blank group by body weight by 2.1 hot plate methods at random, tramadol hydrochloride group, the basic, normal, high dosage group of Gynura divaricata.Blank group gavage tap water, all the other respectively organize the corresponding medicinal liquid of gavage, and administration volume is 10ml/kg.Open intelligent hot-plate instrument, regulate temperature to 55.5 DEG C, after its temperature stabilization, mice is put into analgesic experiment box, observe and record mice from entering experiment box to the time (threshold of pain time value) occurring licking metapedes.To measure respectively before administration and the pain threshold of 60min after administration.If put into analgesic experiment box 60s mice still without licking metapedes reaction, take out (causing scald in order to avoid of long duration) by mice, the threshold of pain time presses 60s and calculates record experimental result.
Response time x100% before threshold of pain increase rate=(after medication before average reaction time-medication average reaction time)/medication
2.2 statistical method are originally tested all results mean ± standard deviation (± s) and are represented.Adopt prism statistical software, compare group difference, using 0.05 or 0.01 as significant difference mark by one factor analysis of variance method (One ?Way ANOVA).
3 results the results are shown in Table 3.Compared with blank group, the threshold of pain increase rate of Gynura divaricata low dose group obviously raises.
Analgesic activity research (± s, n=10) of table 3 Gynura divaricata, the Receptaculum Fici Pumilae
Compared with blank group, * P < 0.05, * * P < 0.01
4 conclusion experimental results show, tramadol hydrochloride group threshold of pain increase rate, apparently higher than blank group, illustrates modeling success.Compared with blank group, the threshold of pain increase rate of Gynura divaricata low dose group obviously raises, and illustrates that Gynura divaricata has analgesic activity.Gynura divaricata wide material sources, without additive, there is in analgesic activity larger Development volue.
Claims (6)
1. the application of Gynura divaricata in the medicine of preparation treatment gouty arthritis.
2. the application of Gynura divaricata according to claim 1 in the medicine of preparation treatment gouty arthritis, is characterized in that: described pharmaceutical dosage form is decoction, mixture, tablet, capsule or granule.
3. treat a medicine for gouty arthritis, effective ingredient comprises Gynura divaricata or is made up of Gynura divaricata single medical material.
4. the medicine for the treatment of gouty arthritis according to claim 3, is characterized in that: described medicine is decoction, Gynura divaricata day dose be 60 ?150 grams, sooner or later take for twice after decocting point.
5. treat a medicine for gouty arthritis, effective ingredient comprises Gynura divaricata extract or is made up of independent Gynura divaricata extract.
6. the medicine for the treatment of gouty arthritis according to claim 5, is characterized in that: described medicine is mixture, tablet, capsule or granule, and Gynura divaricata extract is water extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510229635.3A CN104825517A (en) | 2015-05-07 | 2015-05-07 | Application of gynura divaricata in preparation of drugs for treating gouty arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510229635.3A CN104825517A (en) | 2015-05-07 | 2015-05-07 | Application of gynura divaricata in preparation of drugs for treating gouty arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104825517A true CN104825517A (en) | 2015-08-12 |
Family
ID=53803968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510229635.3A Pending CN104825517A (en) | 2015-05-07 | 2015-05-07 | Application of gynura divaricata in preparation of drugs for treating gouty arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104825517A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106421757A (en) * | 2016-09-09 | 2017-02-22 | 杨森健 | Composition for assisting in treating gout and increasing bone density and application of composition |
| TWI785115B (en) * | 2017-09-18 | 2022-12-01 | 中國商漳州片仔癀藥業股份有限公司 | A kind of total flavonoids extract of Baifengcai and its preparation method and its use in treating hyperuricemia |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101147749A (en) * | 2006-02-21 | 2008-03-26 | 郑乐建 | Divaricate velvetplant medicinal preparation for treating diabetes |
| CN101278957A (en) * | 2007-04-03 | 2008-10-08 | 郑乐建 | Application of extract of Gynura Divaricata in anti-cancer medicine |
| CN101336949A (en) * | 2008-08-21 | 2009-01-07 | 中国食品发酵工业研究院 | Method for extracting polysaccharide and flavone from Gynura divaricata |
| CN102631391A (en) * | 2012-05-15 | 2012-08-15 | 李伟权 | Application of gynura divaricata in preparing lipid-lowering medicine or health-care food |
-
2015
- 2015-05-07 CN CN201510229635.3A patent/CN104825517A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101147749A (en) * | 2006-02-21 | 2008-03-26 | 郑乐建 | Divaricate velvetplant medicinal preparation for treating diabetes |
| CN101278957A (en) * | 2007-04-03 | 2008-10-08 | 郑乐建 | Application of extract of Gynura Divaricata in anti-cancer medicine |
| CN101336949A (en) * | 2008-08-21 | 2009-01-07 | 中国食品发酵工业研究院 | Method for extracting polysaccharide and flavone from Gynura divaricata |
| CN102631391A (en) * | 2012-05-15 | 2012-08-15 | 李伟权 | Application of gynura divaricata in preparing lipid-lowering medicine or health-care food |
Non-Patent Citations (2)
| Title |
|---|
| 南京中医药大学编著: "《中药大辞典》", 31 March 2006, 上海科学技术出版社 * |
| 陈昉 等: ""白子菜提取物对急性痛风性关节炎大鼠模型的抗炎免疫作用"", 《广州中医药大学学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106421757A (en) * | 2016-09-09 | 2017-02-22 | 杨森健 | Composition for assisting in treating gout and increasing bone density and application of composition |
| TWI785115B (en) * | 2017-09-18 | 2022-12-01 | 中國商漳州片仔癀藥業股份有限公司 | A kind of total flavonoids extract of Baifengcai and its preparation method and its use in treating hyperuricemia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9744206B2 (en) | Pharmaceutical compositions for treating cancer of genital system and preparation method therefor | |
| CN104107299A (en) | Traditional Chinese medicine mixture for treating dysmenorrhoea | |
| CN104825517A (en) | Application of gynura divaricata in preparation of drugs for treating gouty arthritis | |
| CN102908403B (en) | Chinese materia medica preparation for treating gout and preparation method thereof | |
| CN104258051B (en) | Traditional Chinese medicine composition for treating gouty arthritis, and preparation method thereof | |
| CN104027684A (en) | Traditional Chinese medicinal composition for treating gout and preparation method thereof | |
| CN101890062B (en) | Use of nardostachys chinensis batal and extract thereof in preparation of medicaments for treating gastric ulcer | |
| CN103585206B (en) | A kind of preparation method of Chrysosplenium extract and application thereof | |
| CN105687672A (en) | Traditional Chinese medicine composition for treating mastitis and mammary gland hyperplasia and preparation method thereof | |
| CN105362798A (en) | Traditional Chinese medicine for treating gouty arthritis and preparation method of traditional Chinese medicine | |
| CN1736425A (en) | Chinese medicinal capsule for treating piles and its preparing process | |
| CN112022988B (en) | Traditional Chinese medicine composition with effect of preventing and/or treating dysmenorrhea and preparation method and application thereof | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN105395650A (en) | Applications of Shu Gan Ning preparation in preparation of medicines treating osteoporosis and complications of the osteoporosis | |
| CN102008072B (en) | Blood pressure lowering edible wild herb food therapy composition | |
| CN107998117B (en) | A kind of combination of oral medication for treating capillary leak syndrome | |
| CN106620318B (en) | Traditional Chinese medicine composition for treating chronic nephritis | |
| CN104800637A (en) | Traditional Chinese medicine composition for treating hyperuricemia with joint swelling | |
| CN117257861A (en) | Application of syringa pubescens extract in preparing analgesic drugs | |
| CN104208307A (en) | Chinese patent medicine treating gout | |
| CN105412291A (en) | Application of Shuganning to preparation of medicine for treating diabetic neuropathy and complications | |
| CN105434600A (en) | Traditional Chinese medicine for treating dampness and heat in liver and gallbladder | |
| CN104825691A (en) | Traditional Chinese medicine composition for treating duodenal ulcer and application of traditional Chinese medicine composition | |
| CN105125988A (en) | Traditional Chinese medicinal preparation for treating thromboangiitis obliterans and preparation method of traditional Chinese medicinal preparation | |
| CN104997818A (en) | Application of total saponins of helleborus thibetanus franch in preparing drugs for preventing and treating liver injuries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150812 |
|
| WD01 | Invention patent application deemed withdrawn after publication |